Table 3.
Summary of reviewed MSC-based therapies aimed to improve engraftment during hematopoietic stem cell transplant in phase 1/2 clinical trials
| Graft | MSC source | MSC dose per kg | Age range, y (n) | Clinical context | Outcome | Reference |
|---|---|---|---|---|---|---|
| PBPC (auto) | BM (auto) | 1 to 2.2 × 106 | Adult (28) | Breast cancer | Hematopoietic recovery | 100 |
| HSCT (allo) | BM (third party) | 1 to 5 × 106 | 1-16 (14) | Hematol dis | Graft acceptance and lymphocyte recovery | 101 |
| HSCT (auto) | BM (third party) | 2 to 5 × 106 | 14-60 (22) | Hematol dis | 73% graft acceptance and neutrophil recovery | 102* |
| UCBT (allo) | BM (parent) | 1 to 10 × 106 | 0-18 (15) | Hematol dis | Hematopoietic recovery | 103 |
| UCBT (allo) | BM (third party) | 1 to 2.2 × 106 | Adult (55) | Hematol dis | NE on engraftment or GVHD prevention | 105 |
| UCBT (allo) | BM (parent) | 1 to 4.9 × 106 | 0-14 (13) | Hematol dis | NE on engraftment or hematopoietic recovery; GVHD prevention | 104 |
| HSCT (allo) | UC (third party) | 5.0 × 105 | 4-31 (21) | Hematol dis | Engraftment; mild GVHD | 108 |
Conditioning regimen for all studies included chemotherapy and total body irradiation.
allo, allograft; auto, autograft; Hematol dis, hematological disorder; HSCT, hematopoietic stem cell transplant; NE, no effect; PBPC, peripheral blood progenitor cell; UC, umbilical cord; UCBT, umbilical cord blood transplant.
*
Randomized clinical trial of patients suffering autograft failure.